Poniard Pharma (PARD) Posts Q3 Loss of $0.29, In-Line with Estimates
More News related to PARD
- Poniard Pharmaceuticals (PARD) Sells 3.5M Shares for Approx $2.15/Share
- Poniard Announces $7.4 Million Financing
- Notable Analyst Rating Changes 11/18: SII, ZMH, FSLR, PHM Upgraded; TGT, ADSK, VIP, JEC, PARD Downgraded
- Morning Movers 11/18: ABK, CHS, LDK, RDN Higher; ONCY, NANO, EXEL, ADSK, CNQR Lower
- Canaccord Adams downgrades Poniard Pharmaceuticals (PARD) to Hold; Less Attractive Risk/Reward
More News related to Earnings
- Icahn Outbids Penn National Gaming (PENN) On Bankrupt Fontainebleau Casino Project
- Overstock.com (OSTK) Dismisses Grant Thorton as Public Accounting Firm
- First Regional Bancorp (FRGB) Announces Adjustment in Taxes and Loan Losses
- NJ Attorney General Stuns TASER International (TASR) and OK's Electronic Control Devices
- Internap Network (INAP) to Amend Poison Pill
Poniard Pharmaceuticals (NASDAQ: PARD) reports Q3 loss of $0.29, even with the analyst estimate of ($0.29).
Related Categories
EarningsStocks Mentioned
-0.20Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
